Company
Headquarters: Nazareth, Belgium
Employees: 2,712
CEO: Mr. Rafael Padilla
€1.32 Billion
EUR as of July 1, 2024
US$1.41 Billion
Company | Market Cap (USD) |
---|---|
Lilly | $808.65 B |
Novo Nordisk | $622.07 B |
UnitedHealth Group | $450.89 B |
Johnson & Johnson | $350.63 B |
Merck | $318.75 B |
Fagron NV, a pharmaceutical compounding company, provides personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients. It prepares personalized ready-to-use medication in its sterile and non-sterile compounding facilities. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. In addition, it offers pharmaceutical raw materials, equipment, and supplies that pharmacists need to prepare medication in the pharmacy. Further, the company develops, manufactures, and supplies mixing equipment that pharmacists can use for the compounding of semi-solid dermatological formulations. It has operations in Europe, the Americas, the Middle East, and Africa, as well as Asia and the Pacific. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.
Top 1-year algo backtest: +265.99%
$10,000 in October 2023 would now be $36,599 by following this algorithm daily at market close.
Use AI to boost your investing & swing trading, now!
Try Disfold DeepFinance FREE
Fagron NV has the following listings and related stock indices.
Stock: FSX: 4A5 wb_incandescent
Stock: OTC: ARSUF wb_incandescent